LexDana ANDA Litigation Intelligence Rankings

Data-driven Hatch-Waxman ANDA rankings — coming 2026.

Hatch-Waxman ANDA litigation rankings covering brand and generic representation across the full lifecycle of Paragraph IV disputes. Built on PACER docket data, FDA Orange Book, and FDA approval records. The first edition publishes in 2026.

Methodology in draft. First edition: 2026.

All
Paragraph IV ANDA cases
Top 100
Firms & attorneys
5 yrs
Rolling window
12+
ANDA-specific signals
The Source

Built on PACER + FDA Orange Book.

Every signal is computed from PACER court records, FDA Orange Book patent listings, and FDA generic approval records. Brand and generic counsel are tracked separately, with 30-month stay clocks, settlement timing, and launch outcomes all extracted.

What we measure

Ranked on activity. Measured on performance.

Six performance signals across both brand and generic representation. Hatch-Waxman has its own rhythm — Paragraph IV certifications, 30-month stays, settlement timing, at-risk launches — and signals reflect that.

01

ANDA case volume

Weighted participation across brand- and generic-side Paragraph IV disputes.

02

Outcome by phase

Win rates across Markman, dispositive motions, trial, and post-trial — on validity and infringement separately.

03

30-month stay strategy

How counsel manages the statutory stay clock — settlement timing, MDL coordination, multi-defendant strategy.

04

Settlement timing & structure

Pre-trial settlement rate and the timing and structure of agreed entry dates and royalties.

05

Generic launch outcomes

Generic-side: launch authorization, 180-day exclusivity capture, at-risk launches and their outcomes.

06

Portfolio & molecule breadth

Therapeutic area and molecule diversity — specialist versus generalist Hatch-Waxman practice.

Why it’s different

Rankings backed by the public record.

Most rankings ask you to make a case for yourself. We already have the evidence.

Based entirely on PACER + FDA public data — no surveys, no peer votes
Tracks both brand-side and generic-side representation
30-month stays, settlement timing, and launch outcomes all included
Normalized for therapeutic area and case stakes
Full methodology published and archived annually
Powered by Patexia — the source of Hatch-Waxman analytics for a decade
Intelligence Badge

The Hatch-Waxman credential, by case outcomes.

When the first edition launches in 2026, firms and attorneys appearing in the Top 100 of any official category — brand or generic — will be eligible to license the LexDana ANDA Intelligence Badge.

  • Display the badge on your firm site, attorney bios, and practice pages
  • Use it in RFP responses, pitch decks, and partner profiles
  • Each badge links to your spotlight page with rank, score, and trend
  • Annual recognition asset, updated when the next year’s rankings drop
Check your eligibility
Coming 2026 · LexDana Intelligence
ANDA Litigation Distinction
Top 100 · Brand-Side
Rank
#TBD
Percentile
Score
YoY Trend